<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198669">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504309</url>
  </required_header>
  <id_info>
    <org_study_id>G214</org_study_id>
    <nct_id>NCT00504309</nct_id>
  </id_info>
  <brief_title>Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides</brief_title>
  <acronym>OMEGA</acronym>
  <official_title>Omacor: Measures of Endothelial Function and triGleride Alteration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reliant Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses
      of an omega-3 fatty acid concentrate in a group of people who normally are not treated for
      high lipids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride levels and lipid profile</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythrocyte fatty acids</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow-mediated dilation</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular reactivity</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating Inflammatory Markers</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin and glucose</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial profile</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 g P-OM3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g P-OM3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 acid ethyl esters</intervention_name>
    <description>4 g P-OM3</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Corn oil placebo</intervention_name>
    <description>4 g Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  triglycerides 150-500 mg/dL

          -  aged 21-65

          -  generally healthy

          -  BMI 20-39

        Exclusion Criteria:

          -  smoking

          -  premenopausal (if female)

          -  use of hormone replacement or oral contraceptives

          -  use of lipid lowering or blood pressure medication

          -  hypertension (BP &gt; 150/95)

          -  peripheral vascular disease

          -  heart disease, diabetes, or stroke

          -  inflammatory disease (e.g. rheumatoid arthritis or crohn's)

          -  elevated liver enzymes

          -  high intake of omega-3 containing foods

          -  allergy to adhesive or latex

          -  use of aspirin, anticoagulants, or SSRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila G West, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Penny M Kris-Etherton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann C Skulas-Ray, B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State University General Clinical Research Center</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <lastchanged_date>July 14, 2010</lastchanged_date>
  <firstreceived_date>July 19, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Sheila West, Ph.D.</name_title>
    <organization>Penn State University</organization>
  </responsible_party>
  <keyword>triglycerides</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>omega-3</keyword>
  <keyword>n-3</keyword>
  <keyword>eicosapentaenoic acid</keyword>
  <keyword>EPA</keyword>
  <keyword>docosahexaenoic acid</keyword>
  <keyword>DHA</keyword>
  <keyword>flow mediated dilation</keyword>
  <keyword>fish</keyword>
  <keyword>Moderate hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
